Table 2 Incremental dose administered per route/regimen for the first 18 subjects as a sentinel group for safety monitoring.

From: Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico

1st dose

Low dose (LD) (107.0 EID50%/dose)

Medium dose (MD) (107.5 EID 50%/dose)

High dose (HD) (108.0 EID 50%/dose)

Day1

Day 2

Day3

Day 4

Day 5

Day 6

Day 7

Day 8

Day 9

IM

S1

S3

S5

S7

S9

S11

S13

S15

S17

IN

S2

S4

S6

S8

S10

S12

S14

S16

S18

  1. Evaluation by an Independent Safety Committee 7 days after the last HD vaccination.
  2. IM intramuscular, IN intranasal, S subject.
Back to article page